When was Deep Genomics founded?

Deep Genomics was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Deep Genomics located?

Deep Genomics is headquartered in Toronto, Canada.

How many employees does Deep Genomics have?

As of Sep 30, 2026, the latest employee count at Deep Genomics is 110.

Is Deep Genomics a funded company?

Deep Genomics is a funded company, having raised a total of $238M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 18, 2015.

When was the latest funding round of Deep Genomics?

Deep Genomics' latest funding was a $***** Series C round on Jul 28, 2021, with participation from 8 investors.

Where does Deep Genomics rank among its competitors?

Deep Genomics ranks 9th amongst 790 active competitors, of which 213 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Deep Genomics?

Deep Genomics' top competitors include Geneoscopy, CureVac and Stoke Therapeutics. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Deep Genomics - 2026 Company Profile, Team, Funding & Competitors

Company Details

AI-powered platform for RNA biology to accelerate genetic therapy discovery. It focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions. Its offers proprietary AI platform including the flagship model BigRNA that uses machine learning to analyze vast RNA biology data, identify therapeutic targets, and evaluate potential therapeutic candidates efficiently than traditional approaches. The technology helps accelerate early stages of drug discovery and design of RNA-based therapies.

Website: www.deepgenomics.com/
Social
Email ID: *****@deepgenomics.com

Key Metrics

Founded Year

2014

Location

Toronto, Canada

Stage

Series C

Total Funding

$238M in 4 rounds

Latest Funding Round

Series C, Jul 28, 2021, $*****

Investors

Khosla Ventures & 17 more

Ranked

9^th among 790 active competitors

Employee Count

110 as on Sep 30, 2026

Similar Companies

OpenEvidence & 3415 more

View Deep Genomics' full profile

Deep Genomics has raised a total funding of $238M over 4 rounds. Its first funding round was on Nov 18, 2015. Its latest funding round was a Series C round on Jul 28, 2021 for $*****. 8 investors participated in its latest round. Deep Genomics has 18 institutional investors.

Here is the list of recent funding rounds of Deep Genomics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 28, 2021	6915892	Series C	2154026	7625518	4439578	8011583
Jan 07, 2020	7132929	Series B	2722825	2120068	2165327	Amplitude & 4 more
Sep 25, 2017	6824725	Series A	5689824	8332422	Khosla Ventures	True Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Deep Genomics's funding rounds and investors

The founders of Deep Genomics are Brendan Frey and Hui Yuan Xiong.

Here are the details of Deep Genomics' key team members:

Brendan Frey: Co-Founder & Chief Innovation Officer of Deep Genomics.
Contact Info: 1 email address
Hui Yuan Xiong: Former Co-Founder of Deep Genomics.

View details of Deep Genomics's Founder profiles and Board Members

Deep Genomics' employee count trend

Deep Genomics has 110 employees as of Sep 26. Here is Deep Genomics's employee count trend over the years:

Uncover Deep Genomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Deep Genomics include Geneoscopy, CureVac and Stoke Therapeutics. Here is the list of Top 10 competitors of Deep Genomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
2nd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
3rd	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Orbimed & 10 others	66/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	66/100
6th	Sarepta 1980, Cambridge (United States), Public	Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases	-	Avoro Capital, Roth Capital Partners & 12 others	63/100
7th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	Nextech Invest, The Column Group & 10 others	62/100
8th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
9th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	Fidelity Investments, Deep Learning & 16 others	62/100
10th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	61/100